KR950704482A - 치료용 항-hiv 올리고누클레오티드 및 이것을 함유하는 약제학적 제형(therapeutic anti-hiv oligonucleotide and pharmaceutical) - Google Patents
치료용 항-hiv 올리고누클레오티드 및 이것을 함유하는 약제학적 제형(therapeutic anti-hiv oligonucleotide and pharmaceutical)Info
- Publication number
- KR950704482A KR950704482A KR1019950701317A KR19950701317A KR950704482A KR 950704482 A KR950704482 A KR 950704482A KR 1019950701317 A KR1019950701317 A KR 1019950701317A KR 19950701317 A KR19950701317 A KR 19950701317A KR 950704482 A KR950704482 A KR 950704482A
- Authority
- KR
- South Korea
- Prior art keywords
- oligonucleotide
- hiv
- seq
- nucleotides
- sequence listing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract 52
- 230000001225 therapeutic effect Effects 0.000 title claims abstract 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 3
- 230000036436 anti-hiv Effects 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 13
- 239000002773 nucleotide Substances 0.000 claims abstract 24
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 23
- 238000009472 formulation Methods 0.000 claims abstract 8
- 239000000203 mixture Substances 0.000 claims abstract 8
- 238000000034 method Methods 0.000 claims abstract 5
- 230000035755 proliferation Effects 0.000 claims abstract 3
- 241000124008 Mammalia Species 0.000 claims abstract 2
- 101710163270 Nuclease Proteins 0.000 claims abstract 2
- 230000029087 digestion Effects 0.000 claims abstract 2
- 150000004713 phosphodiesters Chemical class 0.000 claims abstract 2
- 108020004999 messenger RNA Proteins 0.000 claims 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 3
- 230000001566 pro-viral effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 125000005642 phosphothioate group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
본 발명에서는 HIV-1게놈의 보존된
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 HIV-1 게놈의 표적화된개시 영역 및 그것에 대한 본 발명의 안티센스 포스포티오에이트 누클레오티드의 상보성을 도시한 개략도,
제2도는 표적화된개시 영역 및 본 발명의 25합체를 도시하는 개략도,
제3도는 표적화된개시 영역 및 미츠쿠라등의 28합체를 도시한 개략도.
Claims (24)
- 최소한 하나의 비-포스포디에스테르 누클레오티드간 결합에 의해 결합된 약 25 내지 30누클레오티드를 가지며, 이 결합으로 인해 누클레아제 소화에 대해 올리고 누클레오티드가 내성을 갖게 되는, HIV-1 게놈의 보존된영역의 최소한의 누클레오티드 324 내지 348에 혼성화하는 누클레오티드 서열을 갖고 있는 올리고누클레오티드.
- 제1항에 있어서, 리소한 하나의 비-포스포디에스테르 누클레오티드간 결합이 포스포로티오에이트 결합인 것을 특징으로 하는 올리고누클레오티드.
- 제2항에 있어서, 올리고누클레오티드가 25개의 누클레오티드를 가지는 것을 특징으로 하는 올리고누클레오티드.
- 제3항에 있어서, 서열 목록에서 SEQ ID NO : 1로서 표시된 누클레오티드를 가지는 올리고누클레오티드.
- 제2항에 있어서, 올리고누클레오티드가 26개의 누클레오티드를 가지는 것을 특징으로 하는 올리고누클레오티드.
- 제5항에 있어서, 서열 목록에서 SEQ ID NO : 2로서 표시된 누클레오티드 서열을 가지는 올리고누클레오티드.
- 제5항에 있어서, 서열 목록에서 SEQ ID NO : 3으로서 표시된 누클레오티드 서열을 가지는 올리고누클레오티드.
- 제2항에 있어서, 올리고누클레오티드가 27개의 누클레오티드들 가지는 것을 특징으로 하는 올리고누클레오티드.
- 제8항에 있어서, 서열 목록에서 SEQ ID NO : 4로서 표시된 누클레오티드 서열을 가지는 올리고누클레오티드.
- 제2항에 있어서, 올리고누클레오티드가 28개의 누클레오티드를 가지는 것을 특징으로 하는 을리고누클레오티드.
- 제10항에 있어서, 서열 목록에서 SEQ ID NO : 5로서 표시된 누클레오티드 서열을 가지는 올리고누클레오티드.
- 제10항에 있어서, 서열 목록에서 SEQ ID NO : 6로서 표시된 누클레오티드 서열을 가지는 올리고누클레오티드.
- 제2항에 있어서, 올리고누클레오티드가 29개의 누클레오티드를 가지는 것을 특징으로 하는 올리고누클레오티드.
- 제13항에 있어서, 서열 목록에서 SEQ ID NO : 7로서 표시된 누클레오티드 서열을 가지는 올리고누클레오티드.
- 제2항에 있어서, 올리고누클레오티드가 30개의 누클레오티드를 가지는 것을 특징으로 하는 올리고누클레오티드.
- 제15항에 있어서, 서열 목록에서 SEQ ID NO : 8로서 표시된 누클레오티드 서열을 가지는 올리고누클레오티드.
- 제15항에 있어서, 서열 목록에서 SEQ ID NO : 9로서 표시된 누클레오티드 서열을 가지는 올리고누클레오티드.
- 생리적으로 허용되는 담체중에 제1항의 올리고누클레오티드를 포함하는 치료용 제형.
- 생리적으로 허용되는 담체중에 제4항의 올리고누클레오티드클 포함하는 치료용 제형.
- 제1항의 올리고누클레오티드인 제1의 올리고누클레오티드와 제2의 항-HIV-1 안티센스 올리고누클레오티드를 포함하는 치료용 제형.
- (a)생리적으로 허용되는 담체중에 제1항의 올리고누클레오티드를 포함하는 치료용 제형을 제공하는 단계 ; 그리고 (b)HIV-1 감염된 세포를, 감염된 세포에서 어떠한 HIV-1 프로바이러스 DNA 또는 mRNA의영역에 올리고누클레오티드가 결합되는 것을 가능하게 하기에 충분한 양의 치료용 제형으로 처리하는 단계로 이루어지며, 그로써, 올리고누클레오티드가 HIV-1 DNA또는 mRNA에 결합하여 HIV-1의 증식이 억제되는 것을 특징으로 하는, HIV-1 증식의 억제 방법.
- 제21항에 있어서, 상기 제공 단계가 최소한 하나의 포스포로티오에이트 결합에 의해 결합된 25개의 누클레오티드를 갖는 올리고누클레오티드를 제공하는 것을 포함하며, 올리고누클레오티드의 서열은 서열 목록에서 SEQ ID NO : 1로서 표시되는 것을 특징으로 하는 방법.
- (a)생리적으로 허용되는 담체중에 제1항의 올리고누클레오티드틀 포함하는 치료용 제형을 제공하는 단계 ; 그리고 (b)HIV-1 감염된 세포를, 감염된 세포에서 어떠한 HIV-1 프로바이러스 DNA 또는 mRNA의영역에 올리고누클레오티드가 결합하는 것을 가능하게 하기에 충분한 양의 치료용 제형으로 처리하는 단계로 이루어지며, 그로써, 올리고누클레오티드가 HIV-1 DNA 또는 mRNA에 결합하여 포유류에서 HIV-1 DNA의 발현 및 복제가 억제되는 것을 특징으로 하는, 포유류에서 HIV-1 감염을 치료하는 방법.
- 제23항에 있어서, 상기 제공 단계가 최소한 하나의 포스포로티오에이트 결합에 의해 결합된 25개의 누클레오티드를 갖는 올리고누클레오티드를 제공하는 것을 포함하며, 올리고누클레오티드의 서열은 서열 목록에서 SEQ ID NO : 1로서 표시되는 것을 특징으로 하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95813592A | 1992-10-05 | 1992-10-05 | |
| US958135 | 1992-10-05 | ||
| PCT/US1993/009392 WO1994008004A1 (en) | 1992-10-05 | 1993-10-04 | Therapeutic anti-hiv oligonucleotide and pharmaceutical |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR950704482A true KR950704482A (ko) | 1995-11-20 |
Family
ID=25500631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950701317A Withdrawn KR950704482A (ko) | 1992-10-05 | 1993-10-04 | 치료용 항-hiv 올리고누클레오티드 및 이것을 함유하는 약제학적 제형(therapeutic anti-hiv oligonucleotide and pharmaceutical) |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5684147A (ko) |
| EP (1) | EP0664833B1 (ko) |
| JP (1) | JPH08504570A (ko) |
| KR (1) | KR950704482A (ko) |
| AT (1) | ATE146819T1 (ko) |
| AU (1) | AU678415B2 (ko) |
| BR (1) | BR9307191A (ko) |
| CA (1) | CA2146364A1 (ko) |
| CZ (1) | CZ85495A3 (ko) |
| DE (1) | DE69306969T2 (ko) |
| DK (1) | DK0664833T3 (ko) |
| ES (1) | ES2096343T3 (ko) |
| FI (1) | FI951600L (ko) |
| GR (1) | GR3022315T3 (ko) |
| HU (1) | HUT72400A (ko) |
| NO (1) | NO951307L (ko) |
| NZ (1) | NZ257434A (ko) |
| PL (1) | PL308261A1 (ko) |
| WO (1) | WO1994008004A1 (ko) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5733781A (en) * | 1994-07-19 | 1998-03-31 | Gen-Probe Incorporated | Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus |
| US6776986B1 (en) | 1996-06-06 | 2004-08-17 | Novartis Ag | Inhibition of HIV-1 replication by antisense RNA expression |
| US6610539B1 (en) * | 1997-07-10 | 2003-08-26 | Genesense Technologies, Inc. | Antisense oligonucleotide sequences as inhibitors of microorganisms |
| EP1584681A3 (en) * | 1997-07-10 | 2005-11-09 | GeneSense Technologies Inc. | Antisense oligonucleotide sequences as inhibitors of microorganisms |
| DE69833438T2 (de) | 1997-08-19 | 2006-10-26 | Idera Pharmaceuticals, Inc., Cambridge | Hiv-spezifische oligonukleotide und verfahren zu deren verwendung |
| BR9910643A (pt) | 1998-05-22 | 2001-10-30 | Loeb Health Res Inst At The Ot | Processos e produtos para a indução de imunidadede mucosa |
| AU772847B2 (en) | 1998-11-12 | 2004-05-06 | Invitrogen Corporation | Transfection reagents |
| US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| DE60041489D1 (de) * | 1999-07-09 | 2009-03-19 | Gen Probe Inc | Nachweis von hiv-1 durch amplifizierung von nukleinsäuren |
| US7271148B2 (en) * | 1999-12-23 | 2007-09-18 | The Board Of Regents Of The University Of Texas System | Inhibition of cellular proteases |
| ATE378348T1 (de) * | 2000-01-14 | 2007-11-15 | Us Health | Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion |
| US6582920B2 (en) | 2000-09-01 | 2003-06-24 | Gen-Probe Incorporated | Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations |
| JP2002125687A (ja) * | 2000-10-30 | 2002-05-08 | Tosoh Corp | Ｈｉｖ−１検出のためのオリゴヌクレオチドおよび検出法 |
| US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
| AU2002361468A1 (en) | 2001-08-14 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human S | Method for rapid generation of mature dendritic cells |
| CA2457485C (en) | 2001-08-17 | 2012-08-14 | Arthur M. Krieg | Combination motif immune stimulatory oligonucleotides with improved activity |
| AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
| US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
| US8263091B2 (en) | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
| ATE544466T1 (de) | 2002-10-29 | 2012-02-15 | Coley Pharm Group Inc | Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion |
| EP1578954A4 (en) | 2002-12-11 | 2010-08-11 | Coley Pharm Group Inc | 5'-CPG NUCLEIC ACIDS AND USE METHOD |
| EP1627563A1 (en) | 2004-08-10 | 2006-02-22 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Means and methods for producing a stabilized cell of interest |
| EP1647595A1 (en) * | 2004-10-15 | 2006-04-19 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Nucleic acids against viruses, in particular HIV |
| US8399423B2 (en) * | 2005-10-12 | 2013-03-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| JP5155176B2 (ja) | 2005-11-17 | 2013-02-27 | ティーイーティー システムズ ゲーエムベーハー ウント ツェーオー． カーゲー | 誘導発現系 |
| USRE49583E1 (en) | 2005-11-17 | 2023-07-18 | Tet Systems Gmbh & Co. Kg | Inducible expression systems |
| NZ592159A (en) | 2005-12-09 | 2012-12-21 | Amc Amsterdam | Means and methods for influencing the stability of antibody producing cells |
| WO2007067032A1 (en) | 2005-12-09 | 2007-06-14 | Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
| ES2666584T3 (es) | 2009-07-15 | 2018-05-07 | Aimm Therapeutics B.V. | Medios y métodos para producir anticuerpos de alta afinidad |
| ES2625406T3 (es) | 2010-03-25 | 2017-07-19 | Oregon Health & Science University | Glicoproteínas de CMV y vectores recombinantes |
| DK2646466T3 (en) | 2010-12-02 | 2017-06-06 | Aimm Therapeutics Bv | METHODS AND METHODS FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES |
| PL2691530T3 (pl) | 2011-06-10 | 2019-02-28 | Oregon Health & Science University | Glikoproteiny i rekombinowane wektory CMV |
| US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| CA2958402C (en) | 2013-08-26 | 2021-02-02 | The Royal Institution For The Advancement Of Learning / Mcgill University | Antisense-based small rna agents targeting the gag open reading frame of hiv-1 rna |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| EP3099709B1 (en) | 2014-01-31 | 2019-12-25 | AIMM Therapeutics B.V. | Means and methods for producing stable antibodies |
| CN106572974B (zh) | 2014-07-15 | 2021-04-23 | 生命技术公司 | 用于将分子有效递送到细胞的具有脂质聚集体的组合物和方法 |
| EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0331939B1 (en) * | 1988-02-16 | 2001-11-14 | Greatbatch Gen-Aid, Ltd | Modified cells having resistance to retroviral infection |
| WO1989008146A1 (en) * | 1988-02-26 | 1989-09-08 | Worcester Foundation For Experimental Biology | Inhibition of htlv-iii by exogenous oligonucleotides |
-
1993
- 1993-10-04 WO PCT/US1993/009392 patent/WO1994008004A1/en not_active Application Discontinuation
- 1993-10-04 JP JP6509354A patent/JPH08504570A/ja active Pending
- 1993-10-04 AU AU54028/94A patent/AU678415B2/en not_active Ceased
- 1993-10-04 HU HU9500995A patent/HUT72400A/hu unknown
- 1993-10-04 AT AT93924289T patent/ATE146819T1/de not_active IP Right Cessation
- 1993-10-04 CZ CZ95854A patent/CZ85495A3/cs unknown
- 1993-10-04 EP EP93924289A patent/EP0664833B1/en not_active Expired - Lifetime
- 1993-10-04 PL PL93308261A patent/PL308261A1/xx unknown
- 1993-10-04 KR KR1019950701317A patent/KR950704482A/ko not_active Withdrawn
- 1993-10-04 ES ES93924289T patent/ES2096343T3/es not_active Expired - Lifetime
- 1993-10-04 DE DE69306969T patent/DE69306969T2/de not_active Expired - Fee Related
- 1993-10-04 DK DK93924289.7T patent/DK0664833T3/da active
- 1993-10-04 NZ NZ257434A patent/NZ257434A/en unknown
- 1993-10-04 CA CA002146364A patent/CA2146364A1/en not_active Abandoned
- 1993-10-04 BR BR9307191A patent/BR9307191A/pt not_active Application Discontinuation
-
1994
- 1994-10-07 US US08/319,823 patent/US5684147A/en not_active Expired - Lifetime
-
1995
- 1995-04-04 FI FI951600A patent/FI951600L/fi not_active Application Discontinuation
- 1995-04-04 NO NO951307A patent/NO951307L/no unknown
-
1997
- 1997-01-17 GR GR960403507T patent/GR3022315T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2146364A1 (en) | 1994-04-14 |
| HUT72400A (en) | 1996-04-29 |
| WO1994008004A1 (en) | 1994-04-14 |
| AU5402894A (en) | 1994-04-26 |
| ES2096343T3 (es) | 1997-03-01 |
| EP0664833B1 (en) | 1996-12-27 |
| EP0664833A1 (en) | 1995-08-02 |
| DK0664833T3 (da) | 1997-04-14 |
| BR9307191A (pt) | 1999-03-30 |
| ATE146819T1 (de) | 1997-01-15 |
| NO951307L (no) | 1995-06-01 |
| DE69306969D1 (de) | 1997-02-06 |
| HU9500995D0 (en) | 1995-06-28 |
| FI951600L (fi) | 1995-05-10 |
| CZ85495A3 (en) | 1996-03-13 |
| US5684147A (en) | 1997-11-04 |
| AU678415B2 (en) | 1997-05-29 |
| JPH08504570A (ja) | 1996-05-21 |
| DE69306969T2 (de) | 1997-05-07 |
| GR3022315T3 (en) | 1997-04-30 |
| NZ257434A (en) | 1997-01-29 |
| FI951600A0 (fi) | 1995-04-04 |
| PL308261A1 (en) | 1995-07-24 |
| NO951307D0 (no) | 1995-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR950704482A (ko) | 치료용 항-hiv 올리고누클레오티드 및 이것을 함유하는 약제학적 제형(therapeutic anti-hiv oligonucleotide and pharmaceutical) | |
| Giles et al. | Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures | |
| US5567604A (en) | Anti-viral guanosine-rich oligonucleotides | |
| Iwai et al. | Recognition of the high affinity binding site in rev-response element RNA by the human immunodeficiency virus type-1 rev protein | |
| KR930701466A (ko) | 안티센스 올리고뉴클레오티드에 의한 a형 인플루엔자 바이러스, 안 아아보 스트레인(ann arbor strain)h2n2의 억제 | |
| Cohen | Antisense oligodeoxynucleotides as antiviral agents | |
| Pritchard et al. | Methylphosphonate mapping of phosphate contacts critical for RNA recognition by the human immunodeficiency virus tat and rev proteins | |
| KR960701077A (ko) | 올리고누클레오티드 알킬포스포네이트 및 알킬포스포노티오에이트(oligonucleotide alkylphosphonates and alkylphosphonothioates) | |
| WO1999009154A3 (en) | Novel hiv-specific synthetic oligonucleotides and methods of their use | |
| AU1647095A (en) | Therapeutic ribozyme compositions | |
| Boulmé et al. | Modified (PNA, 2′-O-methyl and phosphoramidate) anti-TAR antisense oligonucleotides as strong and specific inhibitors of in vitro HIV-1 reverse transcription | |
| KR960704033A (ko) | 인간 면역결핍 바이러스에 대한 활성을 갖는 올리고뉴클레오티드(Oligonucleotides with Activity against Humand Immunodeficiency Virus) | |
| CA2494930A1 (en) | Modified forms of interfering rna molecules | |
| RU2020115761A (ru) | МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В | |
| WO1991011535A1 (en) | Inhibition of transcription by double-stranded oligonucleotides | |
| FR2790757B1 (fr) | Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant. | |
| Agrawal et al. | Phosphoramidate, phosphorothioate, and methylphosphonate analogs of oligodeoxynucleotide: inhibitors of replication of human immunodeficiency virus | |
| US8779113B2 (en) | Group of nucleic acid fragments for prevention of HIV infection or AIDS and the usage thereof | |
| Tonkinson et al. | Antisense nucleic acids—prospects for antiviral intervention | |
| Inagawa et al. | Inhibition of human immunodeficiency virus type 1 replication by P‐stereodefined oligo (nucleoside phosphorothioate) s in a long‐term infection model | |
| RU2008130901A (ru) | iPHK-ОПОСРЕДОВАНННОЕ ИНГИБИРОВАНИЕ IGFR ДЛЯ ЛЕЧЕНИЯ ГЛАЗНОГО АНГИОГЕНЕЗА | |
| WO1996023878A1 (en) | Human immunodeficiency virus transcription inhibitors and methods of their use | |
| PRASEUTH et al. | Unexpected effect of an anti-human immunodeficiency virus intermolecular triplex-forming oligonucleotide in an in vitro transcription system due to RNase H-induced cleavage of the RNA transcript | |
| AU2001284570A1 (en) | New sequences | |
| WO2002016608A1 (en) | New sequences |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19950406 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |